Table 5.
Univariate and multivariate logistic regression analyses for predicting successful treatment outcomes in patients with DV.
| GRA score of ≥ 2 | ||||||
|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | |||||
| OR | 95% CI | P value | OR | 95% CI | P value | |
| Urine biomarkers | ||||||
| 8-isoprostane | 0.853 | 0.726–1.003 | 0.054 | |||
| TAC | 0.994 | 0.989–1.000 | 0.033 | 0.995 | 0.990–1.000 | 0.049 |
| Treatment | ||||||
| Biofeedback PFM exercise (ref. EUS BoNT-A injection) | 9.000 | 1.386–58.443 | 0.021 | 7.742 | 0.691–86.731 | 0.097 |
DV Dysfunctional voiding, GRA Global response assessment, TAC Total antioxidant capacity, PFM Pelvic floor muscle, EUS External urethral sphincter, BoNT-A Botulinum toxin A.